Study Overview
A large-scale study led by Chinese researchers, published in the British Medical Journal (BMJ), conducted a head-to-head comparison of 19 existing and emerging obesity drugs. The analysis included 262 clinical trials involving over 99,000 patients, aiming to evaluate differences in weight loss efficacy and heart health benefits.
Key Findings
- Weight loss ranking: The highest weight reduction after one year was achieved with Mounjaro (14.9%) and the yet-unapproved CagriSema (14.8%), followed by Wegovy pill (10.9%), orforglipron pill (9.9%), Wegovy injection (9.8%), and phentermine-topiramate pill (8.1%).
- Heart protection differences: The Wegovy pill matched injections in weight loss but may lack the same heart-protective effects, such as reducing heart attack risk.
- Quality of life: Some drugs failed to 'meaningfully improve quality of life,' while certain injections showed more comprehensive health benefits.
Implications for Consumers
When choosing a weight loss medication, consider not only weight reduction but also long-term effects on heart health and quality of life. The Wegovy pill, as the first oral GLP-1 weight loss drug, offers a needle-free option for eligible patients, but potential gaps in heart protection should be weighed.
The Xiaoshu Health App can sync with Apple Health to track relevant metrics, helping you monitor weight, heart rate, and more for science-based health management.